Raxibacumab, officially designated as PAmAb ABthrax, is a unique therapeutic approach against the disease . This monoclonal protein, designed by ProBioGen AG , specifically interacts with the protective component of Bacillus anthracis, significantly inhibiting its capacity to cause disease . The pro